المؤلفون: Valérie Vilgrain, Helena Pereira, Eric Assenat, Boris Guiu, Alina Diana Ilonca, Georges-Philippe Pageaux, Annie Sibert, Mohamed Bouattour, Rachida Lebtahi, Wassim Allaham, Hélène Barraud, Valérie Laurent, Elodie Mathias, Jean-Pierre Bronowicki, Jean-Pierre Tasu, Rémy Perdrisot, Christine Silvain, René Gerolami, Olivier Mundler, Jean-Francois Seitz, Vincent Vidal, Christophe Aubé, Frédéric Oberti, Olivier Couturier, Isabelle Brenot-Rossi, Jean-Luc Raoul, Anthony Sarran, Charlotte Costentin, Emmanuel Itti, Alain Luciani, René Adam, Maïté Lewin, Didier Samuel, Maxime Ronot, Aurelia Dinut, Laurent Castera, Gilles Chatellier, Elisabeth Delhom - Christol, Alina D Ilonca, Julie Lonjon, Mohamed Abdel-Rehim, Arnaud Dieudonné, Christophe Bazin, Carine Chagneau-Derrode, Patrick Borentain, Antoine Bouvier, Laurent Vervueren, Julia Chalaye, Hicham Kobeiter, Julien Edeline, Etienne Garin, Yan Rolland, Isabelle Archambeaud, Thomas Eugene, Eric Frampas, Christophe Cassinotto, Martine Guyot, Jean-Baptiste Hiriart, Bruno Lapuyade, Julien Vergniol, Philippe Bachellier, Julien Detour, Bernard Duclos, Michel Greget, Francois Habersetzer, Alessio Imperiale, Philippe Merle, Agnès Rode, Julie Morvan, Eric Nguyen-Khac, Thierry Yzet, Guillaume Baudin, Patrick Chevallier, Abakar Mahamat, Thierry Piche, Micheline Razzouk, Patrick Hillon, Romaric Loffroy, Michel Toubeau, Julie Vincent, Gabriele Barabino, Nadia Bouarioua, Muriel Cuilleron, Marie Ecochard, Nathalie Prevot-Bitot, Vincent Leroy, Julie Roux, Christian Sengel, Valérie Bourcier, Nathalie Ganne-Carrie, Olivier Seror, Sylvie Costo, Thông Dao, Jean-Pierre Pelage, Jérôme Dumortier, Francesco Giammarile, Pierre-Jean Valette, Nadia Ghazzar, Olivier Pellerin, Julien Taieb, Pierre Weinmann, Alexandra Heurgue-Berlot, Claude Marcus, Daniele Sommacale, Maria-Angéla Castilla-Lièvre, Sophie Maitre, Lysiane Marthey

المساهمون: Hôpital Beaujon, Hôpital Beaujon-Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CIC - HEGP (CIC 1418), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Eloi, Hôpital Gui de Chauliac, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Hôpital de la Timone [CHU - APHM] (TIMONE), Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Diderot - Paris 7 (UPD7), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)

المصدر: Lancet Oncology
Lancet Oncology, Elsevier, 2017, 18 (12), pp.1624-1636. ⟨10.1016/S1470-2045(17)30683-6⟩

مصطلحات موضوعية: Male, medicine.medical_treatment, Brachytherapy, Administration, Oral, Kaplan-Meier Estimate, Liver transplantation, Gastroenterology, 0302 clinical medicine, Yttrium Radioisotopes, MESH: Carcinoma, Hepatocellular/drug therapy, education.field_of_study, Liver Neoplasms, Radiotherapy Dosage, MESH: Carcinoma, Hepatocellular/radiotherapy, Middle Aged, Sorafenib, Microspheres, MESH: Niacinamide/analogs & derivatives, 3. Good health, MESH: Liver Neoplasms/drug therapy, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Female, 030211 gastroenterology & hepatology, MESH: Phenylurea Compounds/administration & dosage, Liver cancer, medicine.drug, Adult, Niacinamide, medicine.medical_specialty, Carcinoma, Hepatocellular, Population, Antineoplastic Agents, [SDV.CAN]Life Sciences [q-bio]/Cancer, Disease-Free Survival, Drug Administration Schedule, 03 medical and health sciences, Internal medicine, medicine, Carcinoma, Humans, Neoplasm Invasiveness, education, Aged, Neoplasm Staging, Dose-Response Relationship, Drug, Performance status, business.industry, Phenylurea Compounds, medicine.disease, Survival Analysis, Surgery, MESH: Yttrium Radioisotopes/therapeutic use, Liver function, business, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37960b5209b2b33f51aee9e80e06e797Test
https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01727346Test

المؤلفون: Pierre Laurent-Puig, Sylvain Poujol, Françoise Desseigne, S. Thezenas, Thibault Mazard, Evelyne Crapez, Emmanuelle Samalin, E. Francois, Antoine Adenis, T. Conroy, J.F. Seitz, Julien Taieb, M.P. Galais, Jaafar Bennouna, F. Boissière, Marc Ychou, Eric Assenat, O. Bouche, Frédéric Bibeau

المساهمون: CRLCC Val d'Aurelle - Paul Lamarque, Hôpital universitaire Robert Debré [Reims], Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université de Lille-UNICANCER, Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), UNICANCER, CIC - HEGP (CIC 1418), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Léon Bérard [Lyon], Hôpital de la Timone [CHU - APHM] (TIMONE), Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Institut de recherche en cancérologie de Montpellier (IRCM - U896 Inserm - UM1), Université Montpellier 1 (UM1)-CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CRLC Val d'Aurelle-Paul Lamarque, Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Université Lille Nord de France (COMUE)-UNICANCER, UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), CRLCC Val d'Aurelle - Paul Lamarque-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Montpellier 1 (UM1), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Antoine Lacassagne, CRLCC Antoine Lacassagne, CRLCC Oscar Lambret, Institut de Cancérologie de l'Ouest, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Cancérologie de Lorraine - Alexis Vautrin (ICL), Centre Régional de Lutte contre le Cancer François Baclesse (CRLC François Baclesse ), Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)

المصدر: British Journal of Cancer
Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, 2014, 110, pp.1148--54. ⟨10.1038/bjc.2013.813⟩
Breast Cancer Research and Treatment, Springer Verlag, 2014, 110, pp.1148--54. ⟨10.1038/bjc.2013.813⟩

مصطلحات موضوعية: Male, Cancer Research, Colorectal cancer, medicine.medical_treatment, Camptothecin/administration & dosage/analogs & derivatives, Gastroenterology, tyrosine kinase inhibitor, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, 80 and over, clinic, Aged, 80 and over, education.field_of_study, metastatic colorectal cancer, ras Proteins/*genetics, Mutation, Middle Aged, Sorafenib, 3. Good health, Oncology, Disease Progression, Female, Colorectal Neoplasms, medicine.drug, Adult, Niacinamide, medicine.medical_specialty, Niacinamide/administration & dosage/analogs & derivatives, Population, Colorectal Neoplasms/*drug therapy/genetics, [SDV.CAN]Life Sciences [q-bio]/Cancer, Neutropenia, Irinotecan, Disease-Free Survival, Proto-Oncogene Proteins p21(ras), Internal medicine, Proto-Oncogene Proteins, medicine, Humans, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, education, neoplasms, Aged, Chemotherapy, business.industry, Phenylurea Compounds, medicine.disease, digestive system diseases, Surgery, KRAS gene mutation, Regimen, Phenylurea Compounds/administration & dosage, Clinical Study, ras Proteins, Proto-Oncogene Proteins/*genetics, Camptothecin, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0de27d5b42bd45149c4970a8cb5a2512Test
http://europepmc.org/articles/PMC3950852Test

المؤلفون: Antoine Hollebecque, Sonia Extremera, Gilles Salles, Vicente Alfaro, Sandrine Aspeslagh, Mark N. Stein, Emmanuel Gyan, Salvador Fudio, Rastilav Bahleda, Arturo Soto-Matos, Jean-Charles Soria

المساهمون: Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Medical Oncology

المصدر: Anti-Cancer Drugs
Anti-Cancer Drugs, Lippincott, Williams & Wilkins, 2016, ⟨10.1097/CAD.0000000000000457⟩

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Lymphoma, Administration, Oral, Deoxycytidine, Gastroenterology, Depsipeptides/administration & dosage, 0302 clinical medicine, Depsipeptides, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Medicine, Pharmacology (medical), Prospective Studies, Fatigue, Nausea, Antineoplastic Combined Chemotherapy Protocols/administration & dosage, Middle Aged, 3. Good health, 030220 oncology & carcinogenesis, Toxicity, Vomiting, young adult, Female, France, medicine.symptom, medicine.drug, Niacinamide, Sorafenib, Adult, medicine.medical_specialty, Patients, [SDV.CAN]Life Sciences [q-bio]/Cancer, Peptides, Cyclic, 03 medical and health sciences, Niacinamide/administration & dosage, Refractory, Internal medicine, Humans, Adverse effect, Deoxycytidine/administration & dosage, Aged, Lymphoma/drug therapy, Pharmacology, therapy, Dose-Response Relationship, Drug, business.industry, Phenylurea Compounds, toxicity, medicine.disease, Gemcitabine, Thrombocytopenia, Neoplasms/drug therapy, SORAFENIB, 030104 developmental biology, Phenylurea Compounds/administration & dosage, Erythema, business, aged, 80 and over

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a23b85d24896c8e6b050b4cfb9ec050cTest
https://hal.archives-ouvertes.fr/hal-01791282Test

المؤلفون: Lieveke Ameye, Raphaël Maréchal, Amélie Deleporte, Irina Vierasu, Erwin Woff, Thomas Guiot, Camilo Garcia, Alain Hendlisz, Thierry Delaunoit, Gauthier Demolin, Namur Gauthier, Renaud Lhommel, Patrick Flamen, Marc Van den Eynde, Stéphane Holbrechts

المساهمون: UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Service de médecine nucléaire, UCL - (SLuc) Unité d'oncologie médicale, UCL - (SLuc) Centre du cancer

المصدر: European Journal of Nuclear Medicine and Molecular Imaging
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 43, p. 1792-1801 (2016)
European journal of nuclear medicine and molecular imaging, 43 (10

مصطلحات موضوعية: Oncology, Male, Colorectal cancer, medicine.medical_treatment, Phenylurea Compounds -- administration & dosage, 030218 nuclear medicine & medical imaging, Targeted therapy, Tumoral heterogeneity, 0302 clinical medicine, Positron Emission Tomography Computed Tomography, Antineoplastic Combined Chemotherapy Protocols, Radiopharmaceuticals -- pharmacokinetics, Molecular Targeted Therapy, Fluorodeoxyglucose F18 -- pharmacokinetics, Imagerie médicale, radiologie, tomographie, Metastatic colorectal cancer, Colorectal Neoplasms -- diagnostic imaging -- drug therapy -- secondary, General Medicine, Middle Aged, Sorafenib, Treatment Outcome, Drug Monitoring -- methods, Radiology Nuclear Medicine and imaging, 030220 oncology & carcinogenesis, Fdg pet ct, Female, Original Article, Niacinamide -- administration & dosage -- analogs & derivatives, medicine.symptom, Drug Monitoring, Colorectal Neoplasms, medicine.drug, Adult, Niacinamide, medicine.medical_specialty, Sensitivity and Specificity, Capecitabine, Lesion, FDG PET-CT, 03 medical and health sciences, Fluorodeoxyglucose F18, Internal medicine, medicine, Volume reduction, Humans, Molecular Targeted Therapy -- methods, Radiology, Nuclear Medicine and imaging, Aged, business.industry, Phenylurea Compounds, Reproducibility of Results, Positron Emission Tomography Computed Tomography -- methods, medicine.disease, Capecitabine -- administration & dosage, Discontinuation, Antineoplastic Combined Chemotherapy Protocols -- administration & dosage, Radiopharmaceuticals, business, Early metabolic response assessment

وصف الملف: 1 full-text file(s): application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e0aa1f3a5363635b991f75146123099Test
https://pubmed.ncbi.nlm.nih.gov/27072811Test

المؤلفون: Thomas Hundsberger, Dietrich Py, N. Dunkel, A. Ben Aissa, Maria Vargas, Andreas F. Hottinger, Karl Lothard Schaller, Vittoria Espeli, Nicolas Mach, D. Squiban, Damien C. Weber, A Bodmer

المصدر: British Journal of Cancer, vol. 110, no. 11, pp. 2655-2661
British Journal of Cancer
British Journal of Cancer, Vol. 110, No 11 (2014) pp. 2655-2661

مصطلحات موضوعية: Oncology, Male, Cancer Research, medicine.medical_treatment, Pharmacology, urologic and male genital diseases, radiation therapy, tyrosine kinase inhibitor, Antineoplastic Combined Chemotherapy Protocols, heterocyclic compounds, ddc:616, Glioblastoma/mortality/therapy, Brain Neoplasms, Chemoradiotherapy, Middle Aged, Sorafenib, Brain Neoplasms/mortality/therapy, female genital diseases and pregnancy complications, Phase i study, Dacarbazine, Treatment Outcome, Female, Corrigendum, high-grade glioma, medicine.drug, Adult, Niacinamide, medicine.medical_specialty, Niacinamide/administration & dosage/analogs & derivatives, Maximum Tolerated Dose, ddc:616.0757, pharmacokinetic study, Disease-Free Survival, Glioma, Internal medicine, medicine, Temozolomide, Humans, neoplasms, Aged, business.industry, Phenylurea Compounds, medicine.disease, digestive system diseases, ddc:616.8, First line treatment, Radiation therapy, Phenylurea Compounds/administration & dosage, Clinical Study, Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics/therapeutic use/toxicity, Dacarbazine/administration & dosage/analogs & derivatives, business, Glioblastoma

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5769967950cf20f0072e4f151af7bd83Test
https://serval.unil.ch/resource/serval:BIB_A3EE92645B9C.P001/REF.pdfTest

المؤلفون: Pascal Wolter, Alexandra Karadimou, Jean-Jacques Body, Patrick Schöffski, H. Van Poppel, Ludo Willems, Benoit Beuselinck, Philip R. Debruyne, Annick Rogiers, T. van Cann, R. Elaidi, Robert Paridaens, Herlinde Dumez, Joost Berkers, Evelyne Lerut

المصدر: British Journal of Cancer
British Journal of Cancer, 107 (10

مصطلحات موضوعية: Male, Cancer Research, Pathology, Diphosphonates -- administration & dosage -- adverse effects, Indoles, Phenylurea Compounds -- administration & dosage, Antineoplastic Combined Chemotherapy Protocols -- adverse effects -- therapeutic use, Targeted therapy, bone metastases, Renal cell carcinoma, Antineoplastic Combined Chemotherapy Protocols, Bone Density Conservation Agents -- administration & dosage -- adverse effects, Bone Neoplasms -- drug therapy -- pathology -- secondary, Sunitinib, Neoplasm Metastasis, Indoles -- administration & dosage, Outcome, Bone Density Conservation Agents, Diphosphonates, Protein Kinase Inhibitors -- administration & dosage, Osteonecrosis, Bisphosphonates, Sciences bio-médicales et agricoles, Middle Aged, Protein-Tyrosine Kinases, Sorafenib, Prognosis, targeted therapy, Kidney Neoplasms, Treatment Outcome, Oncology, outcome, Female, Niacinamide -- administration & dosage -- analogs & derivatives, Tyrosine kinase, medicine.drug, Carcinoma, Renal Cell -- drug therapy -- pathology -- secondary, Niacinamide, medicine.medical_specialty, renal cell carcinoma, Bone Neoplasms, Osteonecrosis -- chemically induced, Disease-Free Survival, Kidney Neoplasms -- drug therapy -- pathology, Pyrroles -- administration & dosage, medicine, Carcinoma, Humans, Pyrroles, Carcinoma, Renal Cell, Protein Kinase Inhibitors, bisphosphonates, Retrospective Studies, Osteonecrosis of the jaw, business.industry, Protein-Tyrosine Kinases -- antagonists & inhibitors, Bone metastases, Phenylurea Compounds, medicine.disease, osteonecrosis of the jaw, Concomitant, Cancer research, Clinical Study, business

وصف الملف: 1 full-text file(s): application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdb22c4137af4f142fa2a48d0882b042Test
https://pubmed.ncbi.nlm.nih.gov/23132391Test